Faron Pharmaceuticals Oy
FPHAF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 30.62 | 639.75 | -188.25 | 187.24 |
| FCF Yield | -0.01% | -0.00% | -0.00% | -0.06% |
| EV / EBITDA | -38,803.33 | -17,910.49 | -15,797.10 | -18,787.81 |
| Quality | ||||
| ROIC | -0.12% | -0.07% | 1.37% | -0.27% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.24 | 0.60 | 0.67 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -64.25% | 24.16% | 91.13% | 67.50% |
| Safety | ||||
| Net Debt / EBITDA | -355.73 | 1,550.22 | -396.36 | -566.78 |
| Interest Coverage | -1.92 | 0.00 | 0.00 | -0.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -1,806.36 |